Skip to main content

Advertisement

SpringerLink
Log in

Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer

  • Original Article
  • Published:
General Thoracic and Cardiovascular Surgery Aims and scope Submit manuscript

Abstract

Purpose

Fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDGPET/CT) was evaluated as a routine staging technique for primary lung cancer.

Materials and methods

We prospectively compared FDG-PET/CT in determining clinical stage and surgical indication with conventional staging not including positron emission tomography (PET). A total of 50 consecutive patients diagnosed with primary lung cancer by cytological or histological examination were studied; 20 of them underwent surgery.

Results

Discrepancies between the two staging methods were observed in 14 patients (28%). The stage assigned by PET increased in 12 cases (24%) and decreased in 2 (4%). PET staging was accurate in eight cases with otherwise undetected distant metastases (M1) but was incorrect in six cases, including five where it overdiagnosed nodal metastases (N). Two clinical N3 patients (4%) would have missed a chance of surgery if the surgical indication had been determined by PET staging alone. According to our criteria for surgery, other patients were assigned correctly to surgery by PET staging. The maximum standard uptake value (maxSUV) of all primary lesions ranged from 0 to 23.0 (mean ± SD, 8.0 ± 4.4). The mean maxSUV among surgical cases (5.8 ± 3.6) was significantly smaller than among nonsurgical cases (9.5 ± 4.2) (P < 0.05).

Conclusion

Staging examination including FDG-PET/CT and brain magnetic resonance imaging ordinarily can determine the clinical stage and resectability of primary lung cancer. False-positive findings in regional lymph nodes, possibly reflecting past infectious disease, are the most important remaining problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001;2:157–164.

    Article  PubMed  CAS  Google Scholar 

  2. Van Tinteren H, Hoekstra O, Smit E, van den Bergh JH, Schreurs A, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388–1393.

    Article  PubMed  Google Scholar 

  3. Seve P, Billotey C, Broussolle C, Dumontet C, Mackey JR. The role of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2006;109:292–299.

    Article  Google Scholar 

  4. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573–1581.

    Article  PubMed  CAS  Google Scholar 

  5. Kim BT, Kim Y, Lee KS, Yoon SB, Cheon EM, Kwon OJ, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR Am J Roentgenol 1998;170:935–939.

    PubMed  CAS  Google Scholar 

  6. Gonzalez-Stawinski GV, Lemaire A, Merchant F, O’Halloran E, Coleman RE, Harpole DH, et al. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;126:1900–1905.

    Article  PubMed  Google Scholar 

  7. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710–1717.

    Article  PubMed  CAS  Google Scholar 

  8. Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-d-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 2004;125:1413–1423.

    Article  PubMed  Google Scholar 

  9. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011–1019.

    Article  PubMed  Google Scholar 

  10. De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, et al. Additional value of integrated PET-CT in the detection and characterization of lung metastases: correlation with CT alone and PET alone. Eur Radiol 2007;17:467–473.

    Article  PubMed  Google Scholar 

  11. Sloka JS, Hollett PD. Cost effectiveness of positron emission tomography in Canada. Med Sci Monit 2005;11:PH1–PH6.

    PubMed  Google Scholar 

  12. Alzahouri K, Lejeune C, Woronoff-Lemsi MC, Arveux P, Guillemin F. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective. Clin Radiol 2005;60:479–492.

    Article  PubMed  CAS  Google Scholar 

  13. Kramer H, Post WJ, Pruim J, Groen HJ. The prognostic value of positron emission tomography in non-small cell lung cancer: analysis of 266 cases. Lung Cancer 2006;52:213–217.

    Article  PubMed  Google Scholar 

  14. Verhagen AF, Bootsma GP, Tjan-Heijnen VC, van der Wit GJ, Cox AL, Brouwer MH, et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer 2004;44:175–181.

    Article  PubMed  CAS  Google Scholar 

  15. Sachs S, Bilfinger TV. The impact of positron emission tomography on clinical decision making in a university-based multidisciplinary lung cancer practice. Chest 2005;128:698–703.

    Article  PubMed  Google Scholar 

  16. Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130–139.

    Article  PubMed  CAS  Google Scholar 

  17. Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 2006;82:1016–1020.

    Article  PubMed  Google Scholar 

  18. Nomori H, Iwatani K, Kobayashi H, Mori A, Yoshioka S. Omission of mediastinal lymph node dissection in lung cancer: its techniques and diagnostic procedures. Ann Thorac Cardiovasc Surg 2006;12:83–88.

    PubMed  Google Scholar 

  19. Kim BT, Lee KS, Shim SS, Choi JY, Kwon OJ, Kim H, et al. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT—a prospective study. Radiology 2006;41:501–509.

    Article  Google Scholar 

  20. Kurimoto N, Miyazawa T. Endobronchial ultrasonography. Semin Respir Crit Care Med 2004;25:425–431.

    Article  PubMed  Google Scholar 

  21. Wallace MB, Pascual JM, Raimondo M, Woodward TA, McComb BL, Crook JE, et al. Minimally invasive endoscopic staging of suspected lung cancer. JAMA 2008;299:540–546.

    Article  PubMed  CAS  Google Scholar 

  22. Takamochi K, Yoshida J, Murakami K, Niho S, Ishii G, Nishimura M, et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 2005;47:235–242.

    Article  PubMed  Google Scholar 

  23. Kieninger AN, Welsh R, Bendick PJ, Zelenock G, Chmielewski GW. Positron-emission tomography as a prognostic tool for early-stage lung cancer. Am J Surg 2006;191:433–436.

    Article  PubMed  Google Scholar 

  24. Borst GR, Belderbos JS, Boellaard R, Comans EF, de Jaeger K, Lammertsma AA, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 2005;41:1533–1541.

    Article  PubMed  Google Scholar 

  25. Davies A, Tan C, Paschalides C, Barrington SF, O’Doherty M, Utley M, et al. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer 2007;55:75–78.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chest Surgery, Atami Hospital, International University of Health and Welfare, 13-1 Higashikaigan-cho, Atami-shi, Shizuoka, 413-0012, Japan

    Haruhiko Nakamura & Masahiko Taguchi

  2. Department of Pathology, Atami Hospital, International University of Health and Welfare, Shizuoka, Japan

    Hajime Kitamura

  3. Department of Radiology, Atami Hospital, International University of Health and Welfare, Shizuoka, Japan

    Junichi Nishikawa

Authors
  1. Haruhiko Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiko Taguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hajime Kitamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junichi Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haruhiko Nakamura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakamura, H., Taguchi, M., Kitamura, H. et al. Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer. Gen Thorac Cardiovasc Surg 56, 404–409 (2008). https://doi.org/10.1007/s11748-008-0272-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11748-008-0272-5

Key words

Search

Navigation